We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

115 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

50% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 30

0.02% more ownership

Funds ownership: 0.79% → 0.82% (+0.02%)

0% more funds holding

Funds holding: 115 → 115 (0)

0% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 20

23% less capital invested

Capital invested by funds: $232M → $179M (-$53.7M)

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $486K

Holders
115
Holders Change
–
Holders Change %
0%
% of All Funds
2.63%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
20
Increased
45
Reduced
30
Closed
20
Calls
$1K
Puts
$486K
Net Calls
-$485K
Net Calls Change
+$244K

Top Buyers

1
BI
BVF Inc
California
+$10.4M
2
BlackRock
BlackRock
New York
+$5.26M
3
PM
Prosight Management
Texas
+$4.74M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$3.95M
5
American Century Companies
American Century Companies
Missouri
+$2.57M

Top Sellers

1
O
OrbiMed
New York
-$14.3M
2
Morgan Stanley
Morgan Stanley
New York
-$5.2M
3
Millennium Management
Millennium Management
New York
-$4.42M
4
EI
EAM Investors
California
-$3.56M
5
AL
AJO LP
Pennsylvania
-$2.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
101
Barclays
United Kingdom
$20K -$155K -325 -87%
CHP
102
Cable Hill Partners
Oregon
$20K +$5.71K +12 +32%
AIP
103
Ameritas Investment Partners
Nebraska
$15K – – –
PCM
104
Prelude Capital Management
New York
$11K -$20.5K -43 -61%
RBC
105
Roble Belko & Company
Pennsylvania
$10K – – –
RA
106
Royce & Associates
New York
$9K +$7.14K +15 +214%
BNP Paribas Financial Markets
107
BNP Paribas Financial Markets
France
$8.46K -$44.3K -93 -82%
PNC Financial Services Group
108
PNC Financial Services Group
Pennsylvania
$5K – – –
PIA
109
Piedmont Investment Advisors
North Carolina
$5K +$5.23K +11 New
Federated Hermes
110
Federated Hermes
Pennsylvania
$4K -$11.9K -25 -74%
LTFS
111
Ladenburg Thalmann Financial Services
Florida
$4K – – –
Bank of Montreal
112
Bank of Montreal
Ontario, Canada
$2K -$206K -433 -99%
CG
113
Cutler Group
California
$2K -$40.9K -86 -95%
Royal Bank of Canada
114
Royal Bank of Canada
Ontario, Canada
$1K +$952 +2 New
PHK
115
Point72 Hong Kong
Hong Kong
$1K +$1.43K +3 New
EI
116
EAM Investors
California
– -$3.56M -6,518 Closed
AL
117
AJO LP
Pennsylvania
– -$2.96M -5,434 Closed
TCP
118
Tourbillon Capital Partners
New York
– -$2.01M -3,689 Closed
VIA
119
Vident Investment Advisory
Georgia
– -$1.86M -3,595 Closed
3C
120
361 Capital
Colorado
– -$1.51M -2,777 Closed
DZ Bank
121
DZ Bank
Germany
– -$1.02M -1,875 Closed
Ameriprise
122
Ameriprise
Minnesota
– -$880K -1,613 Closed
EGI
123
EAM Global Investors
California
– -$857K -1,570 Closed
AG
124
Algert Global
California
– -$644K -1,181 Closed
VF
125
Virtu Financial
New York
– -$352K -643 Closed
2 3 4
5
6

PVLA Hedge Fund Activity: Q2 2018 in Review

115 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2018, worth a combined $179M — down 23% from $232M a quarter earlier.

Fund positioning in PVLA was balanced in Q2 2018: 20 funds opened new positions, 20 closed out, 45 added to existing stakes and 30 trimmed.

The largest buyer was BVF Inc, adding an estimated $10.4M. The largest seller was OrbiMed, cutting an estimated $14.3M.

  • 115 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $179M of Palvella Therapeutics stock for Q2 2018, down 23% quarter-over-quarter.
  • 20 funds opened new Palvella Therapeutics positions in Q2 2018 and 20 closed out, a net change of 0 holders.
  • The largest Palvella Therapeutics buyer in Q2 2018 was BVF Inc, an estimated $10.4M added.
  • The largest Palvella Therapeutics seller in Q2 2018 was OrbiMed, an estimated $14.3M sold.

Based on aggregated 13F filings for Q2 2018.